Fredun Pharmaceuticals Ltd share price surged by 18.34% to Rs 1313.3 after the company's net profit soared by 21.80% to Rs 13.13 crore, while revenue from operations slightly gained 8.25% to Rs 227.76 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.84 lakh crore, easing 5.15%. It has marginally improved by 1.03% over last one week and advanced by 11.63% in last one month while the market capitalization of Fredun Pharmaceuticals Ltd has sharply increased by 40.44% and 65.89% in the same period respectively. Profit before tax (PBT) of Fredun Pharmaceuticals Ltd stood at Rs 20.55 crore in Q2 FY26, rallying 127.32% year-on-year, and surging by 82.67% quarter-on-quarter. EBITDA came in at Rs 33 crore, expanding by 92.70% YoY and improving 13.37% sequentially. Total expenses posted a minor rise of 6.28% to Rs 199.08 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 179.73 crore, inching up 2.47% YoY, while employee benefits expense was at Rs 7.12 crore, tumbling by 19.64% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 40.21% to Rs 633.33 crore, while net profit saw a strong growth of 65.25% to Rs 32.62 crore, compared to previous TTM. EBITDA jumped by 5712% to Rs 94.54 crore, and PBT witnessed a strong rise of 70.97% to Rs 47.0 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 115.25 crore in FY26, as against Rs 29.06 crore in FY25. Fredun Pharmaceuticals Ltd rallied 265.10% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 2.64% during the same period.
